ABCB1 Variation and Treatment Response in AIDS Patients: Initial Results of the Henan Cohort

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Zhu, Peng ^a   Zhu, Qian ^b   Zhang, Yilei ^a   Ma, Xuejun ^b   Li, Zizhao ^c   Li, Jie ^b   Chen, Jiazhong ^a   Luo, Le ^b   Ring, Huijun Z ^a   Ring, Brian Z ^a   Su, Li ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c Medical Science and Education Building   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 2B6; DIDANOSINE; LAMIVUDINE; MULTIDRUG RESISTANCE PROTEIN 1; NEVIRAPINE; STAVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ABCB1 GENE; ABCC4 GENE; ABCG2 GENE; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; AIDS PATIENT; ANTIBODY DETECTION; ARTICLE; CD25+ T LYMPHOCYTE; CONTROLLED STUDY; CYP2B6 GENE; FEMALE; GENETIC VARIABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHENOTYPIC VARIATION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VALIDATION PROCESS; VIRUS GENE; VIRUS LOAD; VIRUS TRANSMISSION;

ADULT; AGED; ALLELES; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHINA; COHORT STUDIES; FEMALE; GENE FREQUENCY; GENOTYPE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84872875030     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055197     Document Type: Article

References (31)

1. Zhang Kl KL, Ma SJ, (2002) Epidemiology of HIV in China. BMJ 324: 803-804.
2. UNAIDS (2011) HIV in Asia and the Pacific: Getting to Zero. 27.
3. Koralage N, (2004) China to offer free HIV testing and treatment. BMJ 328: 975.
4. Zhang F, Haberer JE, Wang Y, Zhao Y, Ma Y, et al. (2007) The Chinese free antiretroviral treatment program: challenges and responses. AIDS 21Suppl 8: S143-148.
5. Zhang F, Dou Z, Ma Y, Zhang Y, Zhao Y, et al. (2011) Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study. Lancet Infect Dis 11: 516-524.
6. Sun X, Lu F, Wu Z, Poundstone K, Zeng G, et al. (2010) Evolution of information-driven HIV/AIDS policies in China. Int J Epidemiol 39Suppl 2: ii4-13.
7. Ministry of Health AIDS Prevention and Cure Report (2011).
8. Smith MZ, Wightman F, Lewin SR, (2012) HIV reservoirs and strategies for eradication. Curr HIV/AIDS Rep 9: 5-15.
9. Li JY, Li HP, Li L, Li H, Wang Z, et al. (2005) Prevalence and evolution of drug resistance HIV-1 variants in Henan, China. Cell Res 15: 843-849.
10. WHO (2010) Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach.- 2010 rev. Geneva, Switzerland: WHO Press.
11. Gisslen M, Norkrans G, Svennerholm B, Hagberg L, (1997) The effect on human immunodeficiency virus type 1 RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine. J Infect Dis 175: 434-437.
12. Veal GJ, Back DJ, (1995) Metabolism of Zidovudine. Gen Pharmacol 26: 1469-1475.
13. Zhou Z, Rodman JH, Flynn PM, Robbins BL, Wilcox CK, et al. (2006) Model for intracellular Lamivudine metabolism in peripheral blood mononuclear cells ex vivo and in human immunodeficiency virus type 1-infected adolescents. Antimicrob Agents Chemother 50: 2686-2694.
14. Chen CL, Yu G, Venkatachalam TK, Uckun FM, (2002) Metabolism of stavudine-5′-[p-bromophenyl methoxyalaninyl phosphate], stampidine, in mice, dogs, and cats. Drug Metab Dispos 30: 1523-1531.
15. di Iulio J, Fayet A, Arab-Alameddine M, Rotger M, Lubomirov R, et al. (2009) In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics 19: 300-309.
16. Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, et al. (2005) Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis 192: 1931-1942.
17. Chen J, Sun J, Ma Q, Yao Y, Wang Z, et al. (2010) CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients. Ther Drug Monit 32: 573-578.
18. Abla N, Chinn LW, Nakamura T, Liu L, Huang CC, et al. (2008) The human multidrug resistance protein 4 (MRP4, ABCC4): functional analysis of a highly polymorphic gene. J Pharmacol Exp Ther 325: 859-868.
19. Kim HS, Sunwoo YE, Ryu JY, Kang HJ, Jung HE, et al. (2007) The effect of ABCG2 V12M, Q141K and Q126X, known functional variants in vitro, on the disposition of lamivudine. Br J Clin Pharmacol 64: 645-654.
20. Weinberg JL, Kovarik CL, (2010) The WHO Clinical Staging System for HIV/AIDS. Virtual Mentor 12: 202-206.
21. Kwara A, Lartey M, Sagoe KW, Rzek NL, Court MH, (2009) CYP2B6 (c.516G->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. Br J Clin Pharmacol 67: 427-436.
22. Kwara A, Lartey M, Sagoe KW, Kenu E, Court MH, (2009) CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS 23: 2101-2106.
23. Ribaudo HJ, Liu H, Schwab M, Schaeffeler E, Eichelbaum M, et al. (2010) Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J Infect Dis 202: 717-722.
24. Rosenberg MF, Callaghan R, Ford RC, Higgins CF, (1997) Structure of the multidrug resistance P-glycoprotein to 2.5 nm resolution determined by electron microscopy and image analysis. J Biol Chem 272: 10685-10694.
25. Pileri SA, Sabattini E, Falini B, Tazzari PL, Gherlinzoni F, et al. (1991) Immunohistochemical detection of the multidrug transport protein P170 in human normal tissues and malignant lymphomas. Histopathology 19: 131-140.
26. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, et al. (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A 86: 695-698.
27. Sakaeda T, Nakamura T, Okumura K, (2003) Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 4: 397-410.
28. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, et al. (2002) Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359: 30-36.
29. Leschziner GD, Andrew T, Pirmohamed M, Johnson MR, (2007) ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J 7: 154-179.
30. Estrela Rde C, Ribeiro FS, Barroso PF, Tuyama M, Gregorio SP, et al. (2009) ABCB1 polymorphisms and the concentrations of lopinavir and ritonavir in blood, semen and saliva of HIV-infected men under antiretroviral therapy. Pharmacogenomics 10: 311-318.
31. Stormer E, von Moltke LL, Perloff MD, Greenblatt DJ, (2002) Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm Res 19: 1038-1045.